Author/Authors :
Kunovsky, Lumir Department of Gastroenterology - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic , Tesarikova, Pavla Department of Internal Medicine - Hospital Boskovice, Czech Republic , Kala, Zdenek Department of Surgery - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic , Kroupa, Radek Department of Gastroenterology - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic , Kysela, Petr Department of Surgery - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic , Dolina, Jiri Department of Gastroenterology - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic , Trna, Jan Department of Gastroenterology - University Hospital Brno Bohunice - Faculty of Medicine - Masaryk University, Czech Republic
Abstract :
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resistance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curative surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.
